Here's What Key Metrics Tell Us About Qiagen (QGEN) Q1 Earnings
While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates
Qiagen (QGEN) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.47 per share a year ago.
Stay Ahead of the Game With Qiagen (QGEN) Q1 Earnings: Wall Street's Insights on Key Metrics
Get a deeper insight into the potential performance of Qiagen (QGEN) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Activist Fivespan has a stake in Qiagen. Here are 3 levers to boost the company's growth and improve value
Management at Qiagen has done the hard things right, but there is now an opportunity for the company to grow faster and in a more focused way.
QGEN or RGEN: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Qiagen (QGEN) and Repligen (RGEN). But which of these two stocks is more attractive to value investors?
Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is it Worth Retaining QIAGEN Stock in Your Portfolio Now?
QGEN's robust expansion of its testing menu and potential in molecular diagnostics bode well for investors.
QGEN Stock Up on FDA Nod for Second QIAstat-Dx Gastrointestinal Panel
QIAGEN wins the FDA's clearance for the second QIAstat-Dx mini gastrointestinal panel.
Qiagen N.V.: Some Clarity Needed Before Buying The Dip
Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company's free cash flow improved markedly in FY 2024, and the company announced a $300 million stock buyback program last month. An analysis around Qiagen N.V. follows in the paragraphs below.
QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand
QGEN's performance benefits from a resilient portfolio in the fourth quarter of 2024.
